FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039357029> ?p ?o ?g. }

• W2039357029 endingPage "413" @default.
• W2039357029 startingPage "408" @default.
• W2039357029 abstract "► We present the design and results at baseline of an ongoing study. ► This study evaluates the safety and efficacy of rosuvastatin in children with familial hypercholesterolemia. ► Healthy siblings were enrolled as controls. ► At baseline, children with familial hypercholesterolemia had a greater carotid intima-media thickness than their siblings. Background Statin therapy is recommended for children with familial hypercholesterolemia (FH), but most children do not reach treatment targets. Objective Here we present the design and results at baseline of the ongoing CHARON study, to evaluate the safety and efficacy of rosuvastatin. Methods This study comprises an international 2-year open label, titration-to-goal study in 198 children with heterozygous FH aged 6 to 18 years, with rosuvastatin in a maximum dose of 10 mg (<10 years of age) or 20 mg (older children). In addition, 64 unaffected siblings were enrolled as controls. The primary efficacy outcome is the change from baseline in low-density lipoprotein cholesterol, and the secondary outcome is the change in carotid intima-media thickness (c-IMT) in patients with FH compared with their siblings. The primary safety outcomes are growth and sexual maturation; secondary outcomes are the change in other lipoprotein levels and the incidence of adverse events, discontinuation rates, and abnormal laboratory values. Results At baseline, mean age of patients with FH was 12.1 ± 3.3 years, 44% were boys, and mean low-density lipoprotein cholesterol levels were 6.1 ± 1.3 mmol/L (235.9 ± 48.7 mg/dL). Mean c-IMT was 0.399 mm (95% CI, 0.392–0.406 mm) in children with FH versus 0.377 (95% CI, 0.366–0.388 mm) in unaffected siblings (P = .001). Conclusions At baseline, as expected according to on previous observations, children with FH proved to have a greater c-IMT than their healthy siblings. These differences had already occurred at a very young age, which emphasizes the importance of considering early statin initiation in this high-risk population. Statin therapy is recommended for children with familial hypercholesterolemia (FH), but most children do not reach treatment targets. Here we present the design and results at baseline of the ongoing CHARON study, to evaluate the safety and efficacy of rosuvastatin. This study comprises an international 2-year open label, titration-to-goal study in 198 children with heterozygous FH aged 6 to 18 years, with rosuvastatin in a maximum dose of 10 mg (<10 years of age) or 20 mg (older children). In addition, 64 unaffected siblings were enrolled as controls. The primary efficacy outcome is the change from baseline in low-density lipoprotein cholesterol, and the secondary outcome is the change in carotid intima-media thickness (c-IMT) in patients with FH compared with their siblings. The primary safety outcomes are growth and sexual maturation; secondary outcomes are the change in other lipoprotein levels and the incidence of adverse events, discontinuation rates, and abnormal laboratory values. At baseline, mean age of patients with FH was 12.1 ± 3.3 years, 44% were boys, and mean low-density lipoprotein cholesterol levels were 6.1 ± 1.3 mmol/L (235.9 ± 48.7 mg/dL). Mean c-IMT was 0.399 mm (95% CI, 0.392–0.406 mm) in children with FH versus 0.377 (95% CI, 0.366–0.388 mm) in unaffected siblings (P = .001). At baseline, as expected according to on previous observations, children with FH proved to have a greater c-IMT than their healthy siblings. These differences had already occurred at a very young age, which emphasizes the importance of considering early statin initiation in this high-risk population." @default.
• W2039357029 created "2016-06-24" @default.
• W2039357029 creator A5009467334 @default.
• W2039357029 creator A5013031275 @default.
• W2039357029 creator A5020436935 @default.
• W2039357029 creator A5027489789 @default.
• W2039357029 creator A5028321574 @default.
• W2039357029 creator A5040727760 @default.
• W2039357029 creator A5045044313 @default.
• W2039357029 creator A5051194824 @default.
• W2039357029 creator A5070247016 @default.
• W2039357029 creator A5077848934 @default.
• W2039357029 creator A5090781778 @default.
• W2039357029 date "2013-09-01" @default.
• W2039357029 modified "2023-10-13" @default.
• W2039357029 title "Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia" @default.
• W2039357029 cites W1988123993 @default.
• W2039357029 cites W2003487440 @default.
• W2039357029 cites W2070344375 @default.
• W2039357029 cites W2081611571 @default.
• W2039357029 cites W2090231128 @default.
• W2039357029 cites W2105962383 @default.
• W2039357029 cites W2116404316 @default.
• W2039357029 cites W2125639599 @default.
• W2039357029 cites W2130869061 @default.
• W2039357029 cites W2133448117 @default.
• W2039357029 cites W2135545256 @default.
• W2039357029 cites W2154704322 @default.
• W2039357029 cites W2161453510 @default.
• W2039357029 cites W2247997571 @default.
• W2039357029 doi "https://doi.org/10.1016/j.jacl.2013.06.010" @default.
• W2039357029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24079281" @default.
• W2039357029 hasPublicationYear "2013" @default.
• W2039357029 type Work @default.
• W2039357029 sameAs 2039357029 @default.
• W2039357029 citedByCount "15" @default.
• W2039357029 countsByYear W20393570292014 @default.
• W2039357029 countsByYear W20393570292015 @default.
• W2039357029 countsByYear W20393570292016 @default.
• W2039357029 countsByYear W20393570292017 @default.
• W2039357029 countsByYear W20393570292019 @default.
• W2039357029 countsByYear W20393570292021 @default.
• W2039357029 crossrefType "journal-article" @default.
• W2039357029 hasAuthorship W2039357029A5009467334 @default.
• W2039357029 hasAuthorship W2039357029A5013031275 @default.
• W2039357029 hasAuthorship W2039357029A5020436935 @default.
• W2039357029 hasAuthorship W2039357029A5027489789 @default.
• W2039357029 hasAuthorship W2039357029A5028321574 @default.
• W2039357029 hasAuthorship W2039357029A5040727760 @default.
• W2039357029 hasAuthorship W2039357029A5045044313 @default.
• W2039357029 hasAuthorship W2039357029A5051194824 @default.
• W2039357029 hasAuthorship W2039357029A5070247016 @default.
• W2039357029 hasAuthorship W2039357029A5077848934 @default.
• W2039357029 hasAuthorship W2039357029A5090781778 @default.
• W2039357029 hasConcept C120665830 @default.
• W2039357029 hasConcept C121332964 @default.
• W2039357029 hasConcept C126322002 @default.
• W2039357029 hasConcept C187212893 @default.
• W2039357029 hasConcept C197934379 @default.
• W2039357029 hasConcept C2776839432 @default.
• W2039357029 hasConcept C2778163477 @default.
• W2039357029 hasConcept C2778715236 @default.
• W2039357029 hasConcept C2779120738 @default.
• W2039357029 hasConcept C2779339615 @default.
• W2039357029 hasConcept C2780499067 @default.
• W2039357029 hasConcept C2987047532 @default.
• W2039357029 hasConcept C61511704 @default.
• W2039357029 hasConcept C71924100 @default.
• W2039357029 hasConceptScore W2039357029C120665830 @default.
• W2039357029 hasConceptScore W2039357029C121332964 @default.
• W2039357029 hasConceptScore W2039357029C126322002 @default.
• W2039357029 hasConceptScore W2039357029C187212893 @default.
• W2039357029 hasConceptScore W2039357029C197934379 @default.
• W2039357029 hasConceptScore W2039357029C2776839432 @default.
• W2039357029 hasConceptScore W2039357029C2778163477 @default.
• W2039357029 hasConceptScore W2039357029C2778715236 @default.
• W2039357029 hasConceptScore W2039357029C2779120738 @default.
• W2039357029 hasConceptScore W2039357029C2779339615 @default.
• W2039357029 hasConceptScore W2039357029C2780499067 @default.
• W2039357029 hasConceptScore W2039357029C2987047532 @default.
• W2039357029 hasConceptScore W2039357029C61511704 @default.
• W2039357029 hasConceptScore W2039357029C71924100 @default.
• W2039357029 hasFunder F4320307770 @default.
• W2039357029 hasIssue "5" @default.
• W2039357029 hasLocation W20393570291 @default.
• W2039357029 hasLocation W20393570292 @default.
• W2039357029 hasOpenAccess W2039357029 @default.
• W2039357029 hasPrimaryLocation W20393570291 @default.
• W2039357029 hasRelatedWork W1113293211 @default.
• W2039357029 hasRelatedWork W1970484759 @default.
• W2039357029 hasRelatedWork W2037169403 @default.
• W2039357029 hasRelatedWork W2046727692 @default.
• W2039357029 hasRelatedWork W2406715280 @default.
• W2039357029 hasRelatedWork W2416821331 @default.
• W2039357029 hasRelatedWork W2606523900 @default.
• W2039357029 hasRelatedWork W2791266844 @default.
• W2039357029 hasRelatedWork W2899635659 @default.
• W2039357029 hasRelatedWork W3014308787 @default.

• next